Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

Glucose metabolism in Familial Hypobetalipoproteinemia

- candidate number4306
- NTR NumberNTR1510
- ISRCTNISRCTN wordt niet meer aangevraagd
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR29-okt-2008
- Secondary IDs05/223 
- Public TitleGlucose metabolism in Familial Hypobetalipoproteinemia
- Scientific TitleGlucose metabolism in Familial Hypobetalipoproteinemia
- hypothesisWe hypothesize that:
1. Subjects with FHBL have disturbed glucose metabolism, consisting of decreased hepatic insulin sensitivity leading to increased glucose production but increased peripheral insulin sensitivity due to decreased concentrations of IMCL and free fatty acid metabolites.
2. Adiponectin plasma levels are increased due to increased production/ secretion or reduced clearance to compensate for the enhanced glucose production.
- Healt Condition(s) or Problem(s) studiedFamilial Hypobetalipoproteinemia (FHBL), Glucose
- Inclusion criteria1. Subjects with documented FHBL, who have liver steatosis (FHBL group). Healthy subjects (control group), exactly matched for age, sex, body mass index, waist circumference and physical activity
2. Male subjects
3. Age > 18 years
4. Body Mass Index 20-35 kg/m2
5. No participation in other medical intervention studies in the last three months
6. Able to communicate well with the investigator and to comply with the requirements of the study
7. Written informed consent.
- Exclusion criteria1. Known any somatic illness, including neoplasm, metabolic or endocrine disorder, neurologic disorder, active infection, or recent surgical procedures within 3 months of study initiation.
2. Use of medication, which can influence glucose or FFA metabolism (insuline, anabolic steroids, growth hormone, testosteron, DHEA, statines, ACE-inhibitors, AII-antagonists, aspirin)
3. Presence of FHBL linked to chromosome 3p21 (since they have no liver steatosis)
4. History of recreational drug use within the last 30 days, or regular consumption of greater than three units of alcohol per day
5. Diabetes mellitus
6. Seropositive for HbsAg, HbcAg, HCV, HAV or HIV
7. Having a pacemaker or other metal device in the body
8. Claustrophobia
9. Regular exercise above sedentary level.
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingNone
- controlNot applicable
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-nov-2008
- planned closingdate1-feb-2009
- Target number of participants16
- InterventionsSubjects will be studied on 2 occasions:
- after an overnight fast glucose production, disposal and oxidation will be measured using [6,6-2H2]glucose and indirect calorimetry. Lipolysis will be measured using [2H5]glycerol. Muscle metabolites will be measured via muscle biopsy. Subjects will be studied at basal and during a two step hyperinsulinemic euglycemic clamp.
- Hepatic and muscle lipid content will be measured by 1HMRS (magnetic resonance spectroscopy).
Total and regional fat mass will be measured by a DEXA-scan, subcutaneous and visceral fat will be measured by a single slice CT-scan.
- Primary outcomeTo determine in detail:
1) Quantity of liver- and muscle triglycerides
2) Body fat distribution
3) hepatic insulin sensitivity
4) peripheral insulin sensitivity
5) intramyocellular differences regarding fatty acid handling of drug-free subjects with FHBL as compared to healthy controls matched for age, sex, body mass index, waist circumference and physical activity.
- Secondary outcomeAdiponectin levels and levels of different adiponectin forms in plasma.
- Timepoints
- Trial web siteN/A
- statusopen: patient inclusion
- Sponsor/Initiator Academic Medical Center (AMC), Department of Endocrinology and Metabolism
- Funding
(Source(s) of Monetary or Material Support)
Academic Medical Center (AMC), Department of Endocrinology and Metabolism
- PublicationsN/A
- Brief summarySubjects with familial hypobetalipoproteinemia (FHBL) are characterized by low plasma total cholesterol, LDL cholesterol and total apolipoprotein B. Moreover, the prevalence of nonalcoholic fatty livers (steatosis) is increased in these subjects. Hepatic steatosis is associated with hepatic and peripheral insulin resistance and has been suggested to play a role in the pathogenesis of diabetes mellitus type 2 and the metabolic syndrome. Due to the hepatic steatosis in subjects with FHBL, hepatic glucose production could be increased. As peripheral insulin sensitivity is correlated to hepatic insulin sensitivity (in part probably by a common mechanism, namely increased availability and intracellular concentrations of longchain fatty acids and their metabolites and in part by a yet largely unknown direct influence from the liver on peripheral glucose uptake), one could expect peripheral insulin resistance as well. However subjects with FHBL have normal glucose and insulin level s as well as normal oral glucose tolerance tests (OGTT). Two hypotheses can be formulated to explain these findings: A] The existence of increased in stead of decreased peripheral insulin sensitivity. This could be explained by a lower concentration of IMCL (probably a surrogate marker for increased fatty acid metabolites intracellularly) in muscle of subjects with FHBL as they have a dysfunctional triglycerides transport system. B] Increased plasma adiponectin. Adiponectin is produced and secreted by adipose tissue and has an insulin sensitizing effect on glucose metabolism and enhances fatty acid oxidation (which would promote a lower IMCL concentration). In animal experiments, administration of adiponectin stimulated glucose-uptake in muscles and suppressed hepatic glucose output. High levels of adiponectin could counteract the effects of hepatic steatosis on insulin sensitivity in subjects with FHBL. We, therefore, propose a detailed and controlled study of carbohydrate and lipid metabolism in subjects with FHBL and their matched controls, using stable isotopes, combined with measurements of liver and intramyocellular fat content.
- Main changes (audit trail)
- RECORD29-okt-2008 - 7-nov-2008

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar